#USA #New York #Securities Fraud #Rosen Law Firm #ImmunityBio

ImmunityBio Securities Fraud Class Action

Investors who purchased securities of ImmunityBio, Inc. (NASDAQ: IBRX) from January 19 to March 24, 2026, are being encouraged to participate in a class action lawsuit as they may be entitled to compensation for their investments. This comes in the wake of allegations of misconduct leading to a perceived undervaluation of the company’s stock. The suit, initially filed by the well-known Rosen Law Firm, has set a critical deadline for potential lead plaintiffs to come forward by May 26, 2026.

Important Details for Investors

The Rosen Law Firm, recognized for defending investor rights, urges those who bought ImmunityBio shares during the defined class period to take action. The firm has emphasized that participation in this lawsuit does not require upfront costs, as they operate on a contingency fee basis. This means that if there is no financial recovery, investors won’t owe attorney fees. Investors can visit rosenlegal.com for more information on how to get involved and initiate their claims.

The lawsuit alleges that ImmunityBio and its representatives provided misleading statements about the company’s operations and business prospects. A significant claim involves exaggeration regarding the capabilities of a critical product, Anktiva, alleged to be overstated by Patrick Soon-Shiong, a key figure at ImmunityBio. As a result, these statements misled investors, leading to substantial financial losses when the truth about the company’s performance was revealed.

Steps to Join the Class Action

For those interested in joining the class action lawsuit, there are several ways available:

• - Visit the Rosen Law Firm’s website to fill out a submission form.
• - Contact Phillip Kim, Esq., via phone at 866-767-3653 for additional information or clarifications regarding the class action.
• - Investors are also welcome to reach out via email at [email protected] for personal inquiries.

It’s crucial to remember that as of now, no class has been certified. Until this process occurs, investors may need to select counsel or may choose to remain as absent class members, which does not affect their potential to benefit from any future recovery.

Why Choose Rosen Law Firm?

Investors seeking representation are encouraged to finalize their legal counsel soon, as the Rosen Law Firm possesses extensive experience in securities class action litigation. The firm is recognized for handling high-stakes lawsuits, and many of its attorneys are acclaimed within the legal community. It is essential for investors to seek out counsel with a proven track record in similar cases instead of firms that primarily act as intermediaries without actual litigation experience.

Rosen Law Firm’s reputation includes significant settlements in past class actions, particularly against major companies, establishing their effectiveness in recovering losses for investors. Notably, the firm secured over $438 million in recoveries for investors in just one year alone, a testament to the firm’s strong advocacy and skilled approach to legal representation.

Conclusion

ImmunityBio investors should act promptly if they wish to join this class action lawsuit. Understanding their rights and the potential for recovery is vital for those seeking compensation for their investment losses. As the deadline approaches, taking the first steps toward involvement will ensure that investors have a voice in the ongoing legal proceedings against ImmunityBio.

Stay updated on developments regarding this case and similar litigation by following the Rosen Law Firm on their social media platforms like LinkedIn and Twitter for timely updates.